Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPACT: Nab-paclitaxel plus Gemcitabine in LAPC
NCT02301143Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2015
- Primary completion
- Nov 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of nab-paclitaxel in pancreatic cancer (PC), sponsored by Celgene Corporation. Started Apr 2015; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02301143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301143.